Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective, observational study evaluating whether comorbid PsA and obesity impact ustekinumab (UST) persistence in PsO patients using the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR); 10 year follow up study

Next Previous
X
Search
Trial Profile

A retrospective, observational study evaluating whether comorbid PsA and obesity impact ustekinumab (UST) persistence in PsO patients using the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR); 10 year follow up study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ustekinumab (Primary)
  • Indications Psoriasis; Psoriatic arthritis
  • Focus Therapeutic Use

    • Most Recent Events

    • 09 Nov 2021 Results assessing at what extent baseline (BL) factors, such as comorbid PsA and psoriasis (PsO) severity, are associated with ustekinumab (UST) persistence in patients with PsO presented at the ACR Convergence 2021
    • 24 Jun 2021 New trial record
    • 05 Jun 2021 Results presented at the 22nd Annual Congress of the European League Against Rheumatism
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top